1abtik ag
1abtik ag Founded to Fight Sepsis with Novel Antibody Therapeutics
EQS Group-News: 1abtik ag / Key word(s): Market launch 1abtik ag Founded to Fight Sepsis with Novel Antibody Therapeutics Hünenberg/Switzerland, October 26, 2015 The 1abtik ag was recently founded with the sole focus to develop a game-changing antibody-based therapy for sepsis. 1abtik has now entered the financing phase for the drug development process ranging from the identification of lead compounds to running clinical studies including phase 2. Sepsis is a disease with a confirmed very high unmet medical need that may affect any person. It often starts with unspectacular, mostly bacterial but also viral, fungal or parasite infections. However, it then seizes the entire body with a very high rate of mortality of up to 30% – 80%, depending on the severity. Close to 20mio cases of sepsis are assumed worldwide per year. Currently, there are no approved sepsis-specific drugs available. For more information and details, please check www.1abtik.com and/or address fight.sepsis@1abtik.com Contact DISCLAIMER +++++ Additional features: Document: http://n.equitystory.com/c/fncls.ssp?u=IXNRCBNRGG Document title: 1abtik ag 2015-10-26 This Corporate News was distributed by EQS Schweiz AG. www.eqs.com – news archive: http://switzerland.eqs.com/de/News The issuer is responsible for the contents of the release. |
403113 2015-10-26 |